BGNE - ベイジ―ン (BeiGene Ltd.) ベイジ―ン

 BGNEのチャート


 BGNEの企業情報

symbol BGNE
会社名 BeiGene Ltd (ベイジ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ベイジーン(BeiGene Ltd.)は主にバイオ医薬品事業に従事する中国を拠点とする企業である。同社は主に、がんの治療用の革新的分子標的薬および免疫腫瘍薬の研究開発、製造および販売に従事する。同社の主要製品には、ザヌブチニブ(BGB-3111)、チーズリズマブ(BGB-A317)、パミパリブ(BGB-290)がある。   ベイジ―ンはケイマン諸島籍のバイオ医薬品企業。臨床ステ―ジで、主にがん免疫療法の開発に従事。分子標的の抗がん剤候補薬には、BTK(ブルトン型チロシンキナ―ゼ)阻害薬であるRAFタンパク質複合体と、PARP(ポリADPポリキナ―ゼ)阻害薬などを含む。オ―ストラリアとニュ―ジ―ランドで臨床実験を行い、ニュ―ジャ―ジ―州や北京などにオフィスを構える。   BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
本社所在地 c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 CYM
代表者氏名 John V Oyler ジョンVオイラー
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 345-949-4123
設立年月日 40452
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 900人
url www.beigene.com
nasdaq_url https://www.nasdaq.com/symbol/bgne
adr_tso 37297255
EBITDA EBITDA(百万ドル) -254.81800
終値(lastsale) 146.44
時価総額(marketcap) 5461810022.2
時価総額 時価総額(百万ドル) 17144.82
売上高 売上高(百万ドル) 323.73500
企業価値(EV) 企業価値(EV)(百万ドル) 15984.943
当期純利益 当期純利益(百万ドル) -240.77800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Beigene Ltd (ADR) revenues increased from $0K to $85.3M. Net loss increased from $111.2M to $261.5M. Revenues reflect Collaboration revenue increase from $0K to $30.7M. Higher net loss reflects Research and development - Balancing increase from $80.7M to $251.2M (expense) General and administrative - Balancing increase from $15.8M to $60.8M (expense).

 BGNEのテクニカル分析


 BGNEのニュース

   Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment  2020/05/26 08:04:00 Smarter Analyst
Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers. … The post Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment appeared first on Smarter Analyst .
   An expert tech investor beating 97% of his peers reveals the most important trends in his portfolio — and breaks out his top 3 stock picks for the next decade  2020/04/29 12:15:00 Business Insider
Randall Dishmon manages the Invesco Oppenheimer Global Focus Fund, which is delivering positive returns and beating 97% of its competition this year. Dishmon says he seeks out structural trends that will last for years and then finds multiple ways to invest in them. He notes that a powerful enough trend will help numerous companies thrive, and will also result in clearly defined losers. Visit Business Insider's homepage for more stories . It's easy to think of all things that have been stopped by the coronavirus pandemic, like travel, movies, and restaurants — but Randall Dishmon's portfolio is thriving because he invested in things that grew stronger. For 12 years Dishmon has been the sole manager of Invesco's Oppenheimer Global Focus Fund . It's stayed in the black this year even as the S&P 500 index slumped 10%. That puts Dishmon ahead of 97% of his peers at other large-company funds. He says the key is investing in structural growth trends that will shape the world for a decade or more.
   BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China  2019/12/30 16:17:00 Zacks Investment Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
   BeiGene Shares Tumble After Cancer Drug Challenge to Johnson & Johnson Misses Late-Stage Goals  2019/12/16 13:08:10 The Street
BeiGene Ltd BGNE shares slumped lower Monday after the drugmaker said a key cancer treatment, which analyst had pegged as a rival to Johnson & Johnson JNJ, didn't meet goals in a late-stage trial
   BeiGene, Mirati : Preliminary Data from Ongoing Trial Demonstrated Antitumor Activity | MarketScreener  2019/12/13 13:30:03 MarketScreener
By Michael Dabaie BeiGene and Mirati Therapeutics said preliminary data from an ongoing Phase 1b trial of tislelizumab in combination with sitravatinib in patients with platinum-resistant… | December 13, 2019
   An expert tech investor beating 97% of his peers reveals the most important trends in his portfolio — and breaks out his top 3 stock picks for the next decade  2020/04/29 12:15:00 Business Insider
Randall Dishmon manages the Invesco Oppenheimer Global Focus Fund, which is delivering positive returns and beating 97% of its competition this year. Dishmon says he seeks out structural trends that will last for years and then finds multiple ways to invest in them. He notes that a powerful enough trend will help numerous companies thrive, and will also result in clearly defined losers. Visit Business Insider's homepage for more stories . It's easy to think of all things that have been stopped by the coronavirus pandemic, like travel, movies, and restaurants — but Randall Dishmon's portfolio is thriving because he invested in things that grew stronger. For 12 years Dishmon has been the sole manager of Invesco's Oppenheimer Global Focus Fund . It's stayed in the black this year even as the S&P 500 index slumped 10%. That puts Dishmon ahead of 97% of his peers at other large-company funds. He says the key is investing in structural growth trends that will shape the world for a decade or more.
   BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China  2019/12/30 16:17:00 Zacks Investment Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
   BeiGene Shares Tumble After Cancer Drug Challenge to Johnson & Johnson Misses Late-Stage Goals  2019/12/16 13:08:10 The Street
BeiGene Ltd BGNE shares slumped lower Monday after the drugmaker said a key cancer treatment, which analyst had pegged as a rival to Johnson & Johnson JNJ, didn't meet goals in a late-stage trial
   BeiGene, Mirati : Preliminary Data from Ongoing Trial Demonstrated Antitumor Activity | MarketScreener  2019/12/13 13:30:03 MarketScreener
By Michael Dabaie BeiGene and Mirati Therapeutics said preliminary data from an ongoing Phase 1b trial of tislelizumab in combination with sitravatinib in patients with platinum-resistant… | December 13, 2019
   BeiGene : SUPPLEMENT TO THE PROXY STATEMENT FOR THE 2019 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF BEIGENE, LTD. TO BE HELD ON DECEMBER 27, 2019 | MarketScreener  2019/12/08 23:36:04 MarketScreener
This document shall also serve as a supplemental circular to holders of the ordinary shares of BeiGene, Ltd. for purposes of the Rules Governing the Listing of Securities on… | December 9, 2019
   An expert tech investor beating 97% of his peers reveals the most important trends in his portfolio — and breaks out his top 3 stock picks for the next decade  2020/04/29 12:15:00 Business Insider
Randall Dishmon manages the Invesco Oppenheimer Global Focus Fund, which is delivering positive returns and beating 97% of its competition this year. Dishmon says he seeks out structural trends that will last for years and then finds multiple ways to invest in them. He notes that a powerful enough trend will help numerous companies thrive, and will also result in clearly defined losers. Visit Business Insider's homepage for more stories . It's easy to think of all things that have been stopped by the coronavirus pandemic, like travel, movies, and restaurants — but Randall Dishmon's portfolio is thriving because he invested in things that grew stronger. For 12 years Dishmon has been the sole manager of Invesco's Oppenheimer Global Focus Fund . It's stayed in the black this year even as the S&P 500 index slumped 10%. That puts Dishmon ahead of 97% of his peers at other large-company funds. He says the key is investing in structural growth trends that will shape the world for a decade or more.
   BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China  2019/12/30 16:17:00 Zacks Investment Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
   BeiGene Shares Tumble After Cancer Drug Challenge to Johnson & Johnson Misses Late-Stage Goals  2019/12/16 13:08:10 The Street
BeiGene Ltd BGNE shares slumped lower Monday after the drugmaker said a key cancer treatment, which analyst had pegged as a rival to Johnson & Johnson JNJ, didn't meet goals in a late-stage trial
   BeiGene, Mirati : Preliminary Data from Ongoing Trial Demonstrated Antitumor Activity | MarketScreener  2019/12/13 13:30:03 MarketScreener
By Michael Dabaie BeiGene and Mirati Therapeutics said preliminary data from an ongoing Phase 1b trial of tislelizumab in combination with sitravatinib in patients with platinum-resistant… | December 13, 2019
   BeiGene : SUPPLEMENT TO THE PROXY STATEMENT FOR THE 2019 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF BEIGENE, LTD. TO BE HELD ON DECEMBER 27, 2019 | MarketScreener  2019/12/08 23:36:04 MarketScreener
This document shall also serve as a supplemental circular to holders of the ordinary shares of BeiGene, Ltd. for purposes of the Rules Governing the Listing of Securities on… | December 9, 2019

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ベイジ―ン BGNE BeiGene Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)